Evaluation of the Program for Enhanced Review Transparency & Communication for New Molecular Entity NDAs & Original BLAs in Prescription Drug User Fee Act

Forms and Documents

Forms and supporting documents for this ICR

Document	Type	Status	Availability
0746 Change Request Oct 2017.docx	Justification for No Material/Nonsubstantive Change	Uploaded 2017-10-25	Available
BsUFA Reauthorization Performance Goals 2018 through 2022.pdf	Supplementary Document	Uploaded 2017-10-25	Available
PDUFA Reauthorization Performance Goads 2018 through 2022.pdf	Supplementary Document	Uploaded 2017-10-25	Available
0746 Supporting Statement Part A 2016.pdf	Supporting Statement A	Uploaded 2016-07-27	Available

IC Document Collections

Information collection document groups

IC ID	Collection	Type	Status	Form
206912	Interviews	Other-Interview Script	Unchanged
206911	Pretest	Other-Interview Script	Unchanged

ICR Details

OMB Control No: 0910-0746	ICR Reference No: 201710-0910-016
Status: Historical Active	Previous ICR Reference No: 201607-0910-013
Agency/Subagency: HHS/FDA	Agency Tracking No: CDER
Title: Evaluation of the Program for Enhanced Review Transparency & Communication for New Molecular Entity NDAs & Original BLAs in Prescription Drug User Fee Act
Type of Information Collection: No material or nonsubstantive change to a currently approved collection	Common Form ICR:  No
Type of Review Request: Regular
OIRA Conclusion Action: Approved without change	Conclusion Date: 11/14/2017
	Date Received in OIRA: 10/27/2017
Terms of Clearance:

table that charts list comparision

	Inventory as of this Action	Requested	Previously Approved
Expiration Date	09/30/2019	09/30/2019	09/30/2019
Responses	140	0	140
Time Burden (Hours)	211	0	211
Cost Burden (Dollars)	0	0	0

---

Abstract: This information collection involves interviews of pharmaceutical manufacturers who submit new molecular entity (NME) new drug application(NDAs) and original biologics license applications (BLAs) to the Food and Drug Administration (FDA) under the Program for Enhanced Review Transparency and Communication ("the Program") during fiscal years (FYs) 2013-2017. The Program is part of the FDA performance committments under the fifth authorization of the Prescription Drug User Fee Act (PDUFA) that allows FDA to collect user fees for the review of human drug and biologics applications for FYs 2013-2017. The Program is described in detail in Section II.B of the document entitled "PDUFA Reauthorization Performance Goals and Procedures Fiscal Years 2013 through 2017" (the "Commitment Letter). This document specifies that the Program must be evaluated in interim and final assessments by an independent contractor and that these assessments must include interviews of sponsors who submit NME NDAs and original BLAs that are reviewed under the Program. The purpose of these interviews is to collect feedback from applicants on the success of the Program in promoting review transparency and communication during the review process.

---

Authorizing Statute(s): Statute at Large: 126 Stat. 993 Name of Statute: null
  

Citations for New Statutory Requirements: None

---

Associated Rulemaking Information
RIN:	Stage of Rulemaking:	Federal Register Citation:	Date:
	Not associated with rulemaking

---

Federal Register Notices & Comments
60-day Notice:	Federal Register Citation:	Citation Date:
	80 FR 76699	12/10/2015
30-day Notice:	Federal Register Citation:	Citation Date:
	81 FR 47398	07/21/2016
Did the Agency receive public comments on this ICR? No

---

Number of Information Collection (IC) in this ICR: 2

table that charts list of burden

IC Title	Form No.	Form Name
Pretest
Interviews

---

ICR Summary of Burden

table that charts list of burden

	Total Approved	Previously Approved	Change Due to New Statute	Change Due to Agency Discretion	Change Due to Adjustment in Estimate	Change Due to Potential Violation of the PRA
Annual Number of Responses	140	140	0	0	0	0
Annual Time Burden (Hours)	211	211	0	0	0	0
Annual Cost Burden (Dollars)	0	0	0	0	0	0

Burden increases because of Program Change due to Agency Discretion: No

Burden Increase Due to:

Burden decreases because of Program Change due to Agency Discretion: No

Burden Reduction Due to:

Short Statement:

---

Annual Cost to Federal Government: $50,000

Does this IC contain surveys, censuses, or employ statistical methods? No

Does this ICR request any personally identifiable information (see OMB Circular No. A-130 for an explanation of this term)? Please consult with your agency's privacy program when making this determination.     No

Does this ICR include a form that requires a Privacy Act Statement (see 5 U.S.C. §552a(e)(3))? Please consult with your agency's privacy program when making this determination.     No

Is this ICR related to the Affordable Care Act [Pub. L. 111-148 & 111-152]? No

Is this ICR related to the Dodd-Frank Wall Street Reform and Consumer Protection Act, [Pub. L. 111-203]? No

Is this ICR related to the American Recovery and Reinvestment Act of 2009 (ARRA)? No

Is this ICR related to the Pandemic Response? Uncollected

---

Common Form ICR:  No

---

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).

The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:

(a) It is necessary for the proper performance of agency functions;

(b) It avoids unnecessary duplication;

(c) It reduces burden on small entities;

(d) It uses plain, coherent, and unambiguous language that is understandable to respondents;

(e) Its implementation will be consistent and compatible with current reporting and recordkeeping practices;

(f) It indicates the retention periods for recordkeeping requirements;

(g) It informs respondents of the information called for under 5 CFR 1320.8 (b)(3) about:

(i) Why the information is being collected;

(ii) Use of information;

(iii) Burden estimate;

(iv) Nature of response (voluntary, required for a benefit, or mandatory);

(v) Nature and extent of confidentiality; and

(vi) Need to display currently valid OMB control number;

(h) It was developed by an office that has planned and allocated resources for the efficient and effective management and use of the information to be collected.

(i) It uses effective and efficient statistical survey methodology (if applicable); and

(j) It makes appropriate use of information technology.

If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.

Certification Date: 10/27/2017

---